Cargando…
Sequencing of Systemic Therapies in the Management of Advanced Prostate Cancer in India: a Delphi-Based Consensus
INTRODUCTION: With the availability of an increasing number of therapeutic options for advanced prostate cancer (APC), optimal sequencing and combination of therapies have emerged to be the areas of challenges. In the Indian context, there is a dearth of consensus recommendations to guide clinicians...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8757405/ https://www.ncbi.nlm.nih.gov/pubmed/35025089 http://dx.doi.org/10.1007/s40487-021-00181-1 |
_version_ | 1784632673588740096 |
---|---|
author | Desai, Chirag Vaid, Ashok K. Biswas, Ghanashyam Batra, Sandeep Dattatreya, Palanki S. Mohapatra, Prabrajya Narayan Dabkara, Deepak Gore, Adwaita Bhagat, Sagar B. Patil, Saiprasad Barkate, Hanmant |
author_facet | Desai, Chirag Vaid, Ashok K. Biswas, Ghanashyam Batra, Sandeep Dattatreya, Palanki S. Mohapatra, Prabrajya Narayan Dabkara, Deepak Gore, Adwaita Bhagat, Sagar B. Patil, Saiprasad Barkate, Hanmant |
author_sort | Desai, Chirag |
collection | PubMed |
description | INTRODUCTION: With the availability of an increasing number of therapeutic options for advanced prostate cancer (APC), optimal sequencing and combination of therapies have emerged to be the areas of challenges. In the Indian context, there is a dearth of consensus recommendations to guide clinicians regarding optimal sequencing of therapy in APC management. A Delphi-based consensus regarding optimal therapy sequencing in APC management was developed by an expert panel of medical oncologists from across India. METHODS: An expert scientific committee of 11 medical oncologists and an expert panel of 53 medical oncologists from India constituted the panel for the Delphi consensus. In the first phase, a questionnaire with 41 clinical statements was developed in several critical controversial areas in APC treatment. In the second phase, 29 clinical statements were reworked and sent to eight experts to obtain their opinions on best practices. The consensus ratings were based on a 9-point Likert scale. Based on the overall response, statements with a mean score of ≥ 7 with 1 outlier were considered as “consensus.” RESULTS: Degarelix was the preferred androgen deprivation therapy (ADT). While ADT plus docetaxel was the preferred option for metastatic castrate-sensitive/naïve prostate cancer patients with high-volume disease, ADT with abiraterone was the preferred choice for low-volume disease. Docetaxel was the preferred first-line treatment option in men who received ADT alone in the castrate-sensitive/naïve setting. For patients progressing on or after docetaxel for metastatic castrate-resistant prostate cancer (without prior abiraterone or enzalutamide), the experts reached a consensus on the use of enzalutamide as the preferred second-line treatment option. No consensus was reached for the third-line treatment options. CONCLUSION: This article is intended to serve as a guide to help clinicians discuss with their patients as part of the shared and multidisciplinary decision-making for improved APC management in India. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40487-021-00181-1. |
format | Online Article Text |
id | pubmed-8757405 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-87574052022-01-14 Sequencing of Systemic Therapies in the Management of Advanced Prostate Cancer in India: a Delphi-Based Consensus Desai, Chirag Vaid, Ashok K. Biswas, Ghanashyam Batra, Sandeep Dattatreya, Palanki S. Mohapatra, Prabrajya Narayan Dabkara, Deepak Gore, Adwaita Bhagat, Sagar B. Patil, Saiprasad Barkate, Hanmant Oncol Ther Original Research INTRODUCTION: With the availability of an increasing number of therapeutic options for advanced prostate cancer (APC), optimal sequencing and combination of therapies have emerged to be the areas of challenges. In the Indian context, there is a dearth of consensus recommendations to guide clinicians regarding optimal sequencing of therapy in APC management. A Delphi-based consensus regarding optimal therapy sequencing in APC management was developed by an expert panel of medical oncologists from across India. METHODS: An expert scientific committee of 11 medical oncologists and an expert panel of 53 medical oncologists from India constituted the panel for the Delphi consensus. In the first phase, a questionnaire with 41 clinical statements was developed in several critical controversial areas in APC treatment. In the second phase, 29 clinical statements were reworked and sent to eight experts to obtain their opinions on best practices. The consensus ratings were based on a 9-point Likert scale. Based on the overall response, statements with a mean score of ≥ 7 with 1 outlier were considered as “consensus.” RESULTS: Degarelix was the preferred androgen deprivation therapy (ADT). While ADT plus docetaxel was the preferred option for metastatic castrate-sensitive/naïve prostate cancer patients with high-volume disease, ADT with abiraterone was the preferred choice for low-volume disease. Docetaxel was the preferred first-line treatment option in men who received ADT alone in the castrate-sensitive/naïve setting. For patients progressing on or after docetaxel for metastatic castrate-resistant prostate cancer (without prior abiraterone or enzalutamide), the experts reached a consensus on the use of enzalutamide as the preferred second-line treatment option. No consensus was reached for the third-line treatment options. CONCLUSION: This article is intended to serve as a guide to help clinicians discuss with their patients as part of the shared and multidisciplinary decision-making for improved APC management in India. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40487-021-00181-1. Springer Healthcare 2022-01-13 /pmc/articles/PMC8757405/ /pubmed/35025089 http://dx.doi.org/10.1007/s40487-021-00181-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Original Research Desai, Chirag Vaid, Ashok K. Biswas, Ghanashyam Batra, Sandeep Dattatreya, Palanki S. Mohapatra, Prabrajya Narayan Dabkara, Deepak Gore, Adwaita Bhagat, Sagar B. Patil, Saiprasad Barkate, Hanmant Sequencing of Systemic Therapies in the Management of Advanced Prostate Cancer in India: a Delphi-Based Consensus |
title | Sequencing of Systemic Therapies in the Management of Advanced Prostate Cancer in India: a Delphi-Based Consensus |
title_full | Sequencing of Systemic Therapies in the Management of Advanced Prostate Cancer in India: a Delphi-Based Consensus |
title_fullStr | Sequencing of Systemic Therapies in the Management of Advanced Prostate Cancer in India: a Delphi-Based Consensus |
title_full_unstemmed | Sequencing of Systemic Therapies in the Management of Advanced Prostate Cancer in India: a Delphi-Based Consensus |
title_short | Sequencing of Systemic Therapies in the Management of Advanced Prostate Cancer in India: a Delphi-Based Consensus |
title_sort | sequencing of systemic therapies in the management of advanced prostate cancer in india: a delphi-based consensus |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8757405/ https://www.ncbi.nlm.nih.gov/pubmed/35025089 http://dx.doi.org/10.1007/s40487-021-00181-1 |
work_keys_str_mv | AT desaichirag sequencingofsystemictherapiesinthemanagementofadvancedprostatecancerinindiaadelphibasedconsensus AT vaidashokk sequencingofsystemictherapiesinthemanagementofadvancedprostatecancerinindiaadelphibasedconsensus AT biswasghanashyam sequencingofsystemictherapiesinthemanagementofadvancedprostatecancerinindiaadelphibasedconsensus AT batrasandeep sequencingofsystemictherapiesinthemanagementofadvancedprostatecancerinindiaadelphibasedconsensus AT dattatreyapalankis sequencingofsystemictherapiesinthemanagementofadvancedprostatecancerinindiaadelphibasedconsensus AT mohapatraprabrajyanarayan sequencingofsystemictherapiesinthemanagementofadvancedprostatecancerinindiaadelphibasedconsensus AT dabkaradeepak sequencingofsystemictherapiesinthemanagementofadvancedprostatecancerinindiaadelphibasedconsensus AT goreadwaita sequencingofsystemictherapiesinthemanagementofadvancedprostatecancerinindiaadelphibasedconsensus AT bhagatsagarb sequencingofsystemictherapiesinthemanagementofadvancedprostatecancerinindiaadelphibasedconsensus AT patilsaiprasad sequencingofsystemictherapiesinthemanagementofadvancedprostatecancerinindiaadelphibasedconsensus AT barkatehanmant sequencingofsystemictherapiesinthemanagementofadvancedprostatecancerinindiaadelphibasedconsensus |